Eyenovia, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EYEN Nasdaq 2834 www.eyenovia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eyenovia, Inc.

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement - Jun 30th, 2025 6:00 am
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings - Jun 18th, 2025 12:04 pm
Eyenovia Shares Climb After $50 Million Financing to Create HYPE Crypto Reserve - Jun 17th, 2025 1:27 pm
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results - May 19th, 2025 3:30 pm
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) - Apr 10th, 2025 5:00 am
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks - Mar 20th, 2025 1:11 pm
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq - Mar 20th, 2025 5:00 am
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements - Feb 26th, 2025 5:00 am
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives - Feb 24th, 2025 5:00 am
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - Feb 5th, 2025 5:00 am
Top Midday Decliners - Jan 29th, 2025 11:56 am
Eyenovia Announces 1-for-80 Reverse Stock Split - Jan 28th, 2025 2:05 pm
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders - Jan 15th, 2025 5:00 am
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives - Jan 6th, 2025 5:00 am
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - Dec 6th, 2024 6:00 am
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering - Nov 25th, 2024 6:00 am
Eyenovia taking additional actions to reduce personnel-related costs by over 70% - Nov 23rd, 2024 5:05 am
Eyenovia Provides Update on Restructuring Efforts - Nov 22nd, 2024 5:00 am
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright - Nov 19th, 2024 4:15 am
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study - Nov 18th, 2024 7:49 am